Overall survival curves were plotted for patients with pretreatment CDX2 pCTCs >21.5 and those with pretreatment CDX2 pCTCs ⩽21.5, where 21.5 is the median number of pretreatment CDX2 pCTCs from the first cohort of 90 CRC patients. This evidence concerns the gene CDX2 and colorectal carcinoma.